NCT04552366View on ClinicalTrials.gov

A Clinical Trial of a Recombinant Adenovirus 5 Vectored COVID-19 Vaccine (Ad5-nCoV) With Two Doses in Healthy Adults

PHASE1CompletedINTERVENTIONAL

Enrollment

149

Participants

Timeline

Start Date

September 29, 2020

Primary Completion Date

December 31, 2020

Study Completion Date

April 30, 2021

Conditions

COVID-19

Interventions

BIOLOGICAL

Ad5-nCoV

Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)

Trial Locations (1)

430071

Zhongnan Hospital, Wuhan

All Listed Sponsors

collaborator

Zhongnan Hospital

OTHER

lead

Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China

OTHER

NCT04552366 - A Clinical Trial of a Recombinant Adenovirus 5 Vectored COVID-19 Vaccine (Ad5-nCoV) With Two Doses in Healthy Adults | Biotech Hunter | Biotech Hunter